Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer

Liu, Xiaohui; Man, Ya-Nan; Cao, Rui; Liu, Chang; Wu, Xiaoqing

doi:10.1185/03007995.2014.895310

Cited by 4 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liver metastasis in breast cancer patients is an independent prognostic factor for very poor outcomes 4,5 , as median survival of breast cancer patients with liver metastasis ranges from 4.8 to 15 months [6][7][8][9] . In contrast, breast cancer patients with lung or bone metastasis have median survival rates of 9 to 27.4 months 8,9 and 16.3 to 56 months 8,[10][11][12] , respectively. Metastasis is a multistep process, referred to as the metastatic cascade, which begins with tumor cell dissemination in the primary tumor and ends with patient mortality due to the seeding and outgrowth of circulating tumor cells within a distant organ [13][14][15] .…”

Section: Introduction Breast Cancer Metastasis To the Livermentioning

confidence: 99%

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Goddard

Fischer

Schedin

2016

JoVE

View full text Add to dashboard Cite

Breast cancer is the leading cause of cancer-related mortality in women worldwide. Liver metastasis is involved in upwards of 30% of cases with breast cancer metastasis, and results in poor outcomes with median survival rates of only 4.8 -15 months. Current rodent models of breast cancer metastasis, including primary tumor cell xenograft and spontaneous tumor models, rarely metastasize to the liver. Intracardiac and intrasplenic injection models do result in liver metastases, however these models can be confounded by concomitant secondary-site metastasis, or by compromised immunity due to removal of the spleen to avoid tumor growth at the injection site. To address the need for improved liver metastasis models, a murine portal vein injection method that delivers tumor cells firstly and directly to the liver was developed. This model delivers tumor cells to the liver without complications of concurrent metastases in other organs or removal of the spleen. The optimized portal vein protocol employs small injection volumes of 5 -10 μl, ≥ 32 gauge needles, and hemostatic gauze at the injection site to control for blood loss. The portal vein injection approach in Balb/c female mice using three syngeneic mammary tumor lines of varying metastatic potential was tested; high-metastatic 4T1 cells, moderate-metastatic D2A1 cells, and low-metastatic D2.OR cells. Concentrations of ≤ 10,000 cells/injection results in a latency of ~ 20 -40 days for development of liver metastases with the higher metastatic 4T1 and D2A1 lines, and > 55 days for the less aggressive D2.OR line. This model represents an important tool to study breast cancer metastasis to the liver, and may be applicable to other cancers that frequently metastasize to the liver including colorectal and pancreatic adenocarcinomas.

show abstract

Section: Introduction Breast Cancer Metastasis To the Livermentioning

confidence: 99%

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Goddard

Fischer

Schedin

2016

JoVE

View full text Add to dashboard Cite

show abstract

“…The liver is a common site of breast cancer metastasis, along with bone and lung [1][2][3] . Liver metastasis in breast cancer patients is an independent prognostic factor for very poor outcomes 4,5 , as median survival of breast cancer patients with liver metastasis ranges from 4.8 to 15 months [6][7][8][9] . In contrast, breast cancer patients with lung or bone metastasis have median survival rates of 9 to 27.4 months 8,9 and 16.3 to 56 months 8,10-12 , respectively.…”

Section: Introduction Breast Cancer Metastasis To the Livermentioning

confidence: 99%

“…Liver metastasis in breast cancer patients is an independent prognostic factor for very poor outcomes 4,5 , as median survival of breast cancer patients with liver metastasis ranges from 4.8 to 15 months [6][7][8][9] . In contrast, breast cancer patients with lung or bone metastasis have median survival rates of 9 to 27.4 months 8,9 and 16.3 to 56 months 8,10-12 , respectively. Metastasis is a multistep process, referred to as the metastatic cascade, which begins with tumor cell dissemination in the primary tumor and ends with patient mortality due to the seeding and outgrowth of circulating tumor cells within a distant organ [13][14][15] .…”

Section: Introduction Breast Cancer Metastasis To the Livermentioning

confidence: 99%

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Goddard

Fischer²,

Schedin³

2016

JoVE

View full text Add to dashboard Cite

“…7) As for breast cancer, drug combinations (such as vinorelbine-cisplatin and capecitabinevinorelbine) are indeed commonly used in clinical treatment and have shown excellent results. 8,9) With the development of next-generation sequencing technology in the past decade, epigenetic processes have been found to play a key role in the causation, progression and treatment of cancer.…”

mentioning

confidence: 99%